<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01651403</url>
  </required_header>
  <id_info>
    <org_study_id>GS-US-174-0144</org_study_id>
    <secondary_id>2012-000586-20</secondary_id>
    <nct_id>NCT01651403</nct_id>
  </id_info>
  <brief_title>Evaluating the Efficacy, Safety and Tolerability of Tenofovir DF in Pediatric Patients With Chronic Hepatitis B Infection</brief_title>
  <official_title>A Randomized, Double-Blind Evaluation of the Antiviral Efficacy, Safety, and Tolerability of Tenofovir Disoproxil Fumarate Versus Placebo in Pediatric Patients With Chronic Hepatitis B Infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gilead Sciences</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Gilead Sciences</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This placebo-controlled study evaluates the efficacy, safety and tolerability of tenofovir
      disoproxil fumarate (TDF) in participants 2 to &lt; 12 years old with chronic Hepatitis B
      infection. While studies have shown significant virologic response in adults and adolescents,
      the effect in children is not well established. This study will provide valuable data that
      can help establish the efficacy and safety profiles of TDF in children. The study will
      consist of 48 weeks of blinded randomized treatment, after which participants will switch to
      open-label TDF treatment for an additional 144 weeks.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">December 6, 2012</start_date>
  <completion_date type="Anticipated">March 2025</completion_date>
  <primary_completion_date type="Actual">August 7, 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of Participants with Serum HBV DNA &lt; 400 Copies/mL (69 IU/mL) at Week 48</measure>
    <time_frame>Week 48</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of Participants with Hepatitis B e Antigen (HBeAg) Seroconversion at Week 48</measure>
    <time_frame>Week 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Participants with Normal ALT and Normalization of ALT</measure>
    <time_frame>Week 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Composite Endpoint of Proportion of Participants with HBV DNA &lt; 400 Copies/mL (69 IU/mL) and Normalized ALT</measure>
    <time_frame>Week 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Participants with HBV DNA &lt; 169 Copies/mL (29 IU/mL)</measure>
    <time_frame>Week 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportions of Participants with HBsAg Loss and Seroconversion</measure>
    <time_frame>Week 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sequence Changes From Baseline Within the HBV Polymerase for Participants who Were Viremic (HBV DNA ≥ 400 Copies/mL [69 IU/mL]) at Weeks 48, 96, 144, 192 or Early Discontinuation; Including Participants with Confirmed Virologic Breakthrough</measure>
    <time_frame>Baseline; Weeks 48, 96, 144, 192 or Early Discontinuation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative Incidence of at least 4% Decrease From Baseline in Bone Mineral Density of Lumbar Spine</measure>
    <time_frame>Baseline; Week 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change from Baseline in Bone Mineral Density of Lumbar Spine</measure>
    <time_frame>Baseline; Week 48</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Chronic Hepatitis B Infection</condition>
  <arm_group>
    <arm_group_label>Tenofovir DF (Blinded Randomized Treatment)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive tenofovir disoproxil fumarate (tenofovir DF; TDF) for 48 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo to match TDF (Blinded Randomized Treatment)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants will receive TDF placebo for 48 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Tenofovir DF (Open-label Treatment)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Following 48 weeks of blinded randomized treatment, participants will switch to open-label TDF treatment for an additional 144 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Tenofovir DF (Open-label Extension Phase)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Following the completion of study at Week 192, participants may have the option to receive open-label TDF until it is commercially available in that country for treatment of chronic HBV in patients of their age and weight.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tenofovir DF</intervention_name>
    <description>Participants weighing ≥ 17 kg will receive TDF one tablet administered orally once daily (150, 200, 250 or 300 mg tablets based on body weight).
Participants weighing &lt; 17 kg or ≥ 17 kg who are unable to swallow a tablet will receive TDF oral powder in a dose of 8 mg/kg once daily up to a maximum dose of 300mg.</description>
    <arm_group_label>Tenofovir DF (Blinded Randomized Treatment)</arm_group_label>
    <arm_group_label>Tenofovir DF (Open-label Treatment)</arm_group_label>
    <arm_group_label>Tenofovir DF (Open-label Extension Phase)</arm_group_label>
    <other_name>Viread®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TDF Placebo</intervention_name>
    <description>Participants weighing ≥ 17 kg will receive TDF placebo tablet administered orally once daily.
Participants weighing &lt; 17 kg or ≥ 17 kg who are unable to swallow a tablet will receive TDF placebo oral powder once daily.</description>
    <arm_group_label>Placebo to match TDF (Blinded Randomized Treatment)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

          -  Male or Female, 2 to &lt; 12 years of age

          -  Weight ≥ 10kg

          -  Chronic HBV infection ≥ 6 months

          -  HBeAg-positive or HBeAg-negative

          -  HBV Viral Load ≥ 100,000 copies/mL

          -  Alanin aminotransferase (ALT) ≥ 1.5 x the upper limit of the normal range (ULN) at
             screening

          -  Creatinine Clearance ≥ 80 mL/min

          -  Absolute neutrophil count (ANC) ≥ 1,500/mm^3, hemoglobin ≥ 10g/dL

          -  Negative pregnancy test at screening

          -  No prior tenofovir DF therapy (subjects may have received prior interferon‑alfa and/or
             other oral anti‑HBV nucleoside/nucleotide therapy; subjects must have discontinued
             interferon-alfa therapy ≥ 6 months prior to screening; subjects experienced on other
             anti-HBV nucleoside/nucleotide therapy must have discontinued therapy ≥ 16 weeks prior
             to screening to avoid flare if randomized to the placebo arm)

        Key Exclusion Criteria:

          -  Pregnant or lactating

          -  Decompensated liver disease

          -  Received interferon therapy within 6 months of Screening

          -  Received anti-HBV nucleoside/nucleotide therapy within 16 weeks of Screening

          -  Alpha-fetoprotein levels &gt; 50 ng/mL

          -  Evidence of hepatocellular carcinoma (HCC)

          -  Co-infection with HIV, acute hepatitis A virus (HAV), hepatitis C virus (HCV), or
             hepatitis D virus (HDV)

          -  Chronic liver disease not due to HBV

          -  History of significant renal, cardiovascular, pulmonary, neurological or bone disease

          -  Long term non-steroidal, anti-inflammatory drug therapy

        Note: Other protocol defined Inclusion/Exclusion criteria may apply
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>11 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gilead Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Gilead Sciences</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Phoenix Children's Hospital</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California, San Francisco</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital Colorado</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New York University School of Medicine</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cincinnati Children's Hospital Medical Center</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Children's Hospital</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Multiprofile Hospital for Active Treatment Sveti Georgi</name>
      <address>
        <city>Plovdiv</city>
        <zip>4002</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nirmal Hospital Private Limited</name>
      <address>
        <city>Surat</city>
        <state>Gujrat</state>
        <zip>395 002</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medanta -The Medicity</name>
      <address>
        <city>Gurgaon</city>
        <state>Haryana</state>
        <zip>122 001</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Colors Children Hospital</name>
      <address>
        <city>Nagpur</city>
        <state>Maharashtra</state>
        <zip>440012</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SMS Medical College and Hospital</name>
      <address>
        <city>Jaipur</city>
        <state>Rajasthan</state>
        <zip>302004</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>M.V. Hospital and Research Centre 314/30 Mirza Mandi Chowk</name>
      <address>
        <city>Lucknow</city>
        <state>Uttar Pradesh</state>
        <zip>226003</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. John Hospital &amp; Medical Center</name>
      <address>
        <city>Bangalore</city>
        <zip>560034</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pusan National University Yangsan Hospital</name>
      <address>
        <city>Yangsan-si</city>
        <state>Gyeongnam</state>
        <zip>626 770</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kyungpook National University</name>
      <address>
        <city>Daegu</city>
        <zip>700-721</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Severance Children's Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>120-752</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Samsung Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>135-710</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Asan Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>138-736</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Grigore Alexandrescu Emergency Clinical Hospital for Children</name>
      <address>
        <city>Bucharest</city>
        <zip>011743</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fundeni Clinical Institute - Constantinesco</name>
      <address>
        <city>Bucharest</city>
        <zip>022328</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Victor Babes Clinical Hospital of Infectious Diseases and Pneumophtisology</name>
      <address>
        <city>Craiova</city>
        <zip>200515</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Taiwan University Hospital</name>
      <address>
        <city>Taipei</city>
        <zip>100</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Taipei Veterans General Hospital</name>
      <address>
        <city>Taipei</city>
        <zip>11217</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Bulgaria</country>
    <country>India</country>
    <country>Korea, Republic of</country>
    <country>Romania</country>
    <country>Taiwan</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Poland</country>
  </removed_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 25, 2012</study_first_submitted>
  <study_first_submitted_qc>July 25, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 27, 2012</study_first_posted>
  <last_update_submitted>January 24, 2018</last_update_submitted>
  <last_update_submitted_qc>January 24, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 26, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hepatitis</keyword>
  <keyword>Hepatitis B</keyword>
  <keyword>HBV</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis, Chronic</mesh_term>
    <mesh_term>Hepatitis B</mesh_term>
    <mesh_term>Hepatitis B, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tenofovir</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

